Libtayo (cemiplimab-rwlc) / Regeneron 
Welcome,         Profile    Billing    Logout  
 1 Disease   67 Trials   67 Trials   1555 News 


«12...89101112131415161718...3940»
  • ||||||||||  Adrenal insufficiency in patients on immune checkpoint inhibitors: () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_4689;    
    Future prospective studies will be needed to confirm this finding. Physicians, particularly oncologists and endocrinologists, should have a high index of suspicion for adrenal insufficiency in patients on immune checkpoint inhibitors.
  • ||||||||||  Libtayo (cemiplimab) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD), fianlimab (REGN3767) / Regeneron, Sanofi
    A phase 3 trial of fianlimab (anti (On Demand | Hall A; Poster Bd # 360a) -  Apr 26, 2023 - Abstract #ASCO2023ASCO_2576;    
    P3
    The study is currently open for enrollment. Clinical trial information: NCT05352672.
  • ||||||||||  Libtayo (cemiplimab) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD), fianlimab (REGN3767) / Regeneron, Sanofi
    A phase 3 trial comparing fianlimab (anti (On Demand | Hall A; Poster Bd # 358a) -  Apr 26, 2023 - Abstract #ASCO2023ASCO_2572;    
    P3
    The first analysis will be performed when 242 RFS events have been observed. Clinical trial information: NCT05608291.
  • ||||||||||  Libtayo (cemiplimab) / Regeneron
    Review, Journal:  Cutaneous squamous cell carcinoma: state of the art, perspectives and unmet needs. (Pubmed Central) -  Apr 19, 2023   
    The immune checkpoint inhibitor cemiplimab is approved and recommended as the treatment of first choice for locally advanced or metastatic cSCC in Europe...Much research is still needed for solid organ transplant patients, concomitant hematologic diseases, and cSCC showing primary or acquired resistance to immunotherapies. Current developments include new drug combinations, intralesional therapies alone or in combination with immune checkpoint inhibitors, and neoadjuvant approaches.
  • ||||||||||  SAR444200 / Sanofi
    Trial completion date, Trial primary completion date, Metastases:  Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov) -  Apr 18, 2023   
    P1/2,  N=106, Recruiting, 
    Current developments include new drug combinations, intralesional therapies alone or in combination with immune checkpoint inhibitors, and neoadjuvant approaches. Trial completion date: May 2029 --> May 2030 | Trial primary completion date: May 2029 --> May 2030
  • ||||||||||  Libtayo (cemiplimab) / Regeneron
    Journal:  The Cutaneous Squamous Cell Carcinoma - An Update (Pubmed Central) -  Apr 14, 2023   
    Multidisciplinary board decisions are mandatory for all patients with advanced disease who require more than surgery. Further development of existing therapeutic concepts, identification of new combination therapies and the development of new immunotherapeutics will be the key challenge over the next few years.
  • ||||||||||  HST-1011 / HotSpot Therap
    Enrollment open, Monotherapy, IO biomarker:  SOLAR1: A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody (clinicaltrials.gov) -  Apr 14, 2023   
    P1/2,  N=203, Recruiting, 
    Further development of existing therapeutic concepts, identification of new combination therapies and the development of new immunotherapeutics will be the key challenge over the next few years. Not yet recruiting --> Recruiting
  • ||||||||||  pegenzileukin (SAR444245) / Sanofi, Libtayo (cemiplimab-rwlc) / Regeneron
    Trial completion date, Trial initiation date, Trial suspension, Trial primary completion date:  Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma (clinicaltrials.gov) -  Apr 7, 2023   
    P2,  N=26, Suspended, 
    Initiation date: Aug 2023 --> Aug 2022 Trial completion date: Oct 2024 --> Apr 2027 | Initiation date: Feb 2023 --> Aug 2023 | Not yet recruiting --> Suspended | Trial primary completion date: Oct 2024 --> Apr 2027
  • ||||||||||  Voyager-V1 / Vyriad
    Clinical Activity of Oncolytic Virus Voyager-V1 in Patients with Relapsed Refractory Lymphoma (Room 501 ABC) -  Apr 6, 2023 - Abstract #ASGCT2023ASGCT_1005;    
    Adverse events were manageable, with transient decreases in lymphocyte counts and grade 1-2 cytokine release syndrome that is transient and resolving by 24h. Two cohort are added to the study to enroll 20 additional T cell lymphoma and 10 additional B cell lymphoma patients to obtain additional safety and efficacy signal and deeper analysis of biomarkers of responses.
  • ||||||||||  Libtayo (cemiplimab-rwlc) / Regeneron
    Enrollment closed:  CONTRAC: Cemiplimab in AlloSCT/SOT Recipients With CSCC (clinicaltrials.gov) -  Mar 28, 2023   
    P1,  N=12, Active, not recruiting, 
    Trial completion date: Apr 2026 --> Mar 2027 | Trial primary completion date: Apr 2026 --> Mar 2027 Recruiting --> Active, not recruiting
  • ||||||||||  A Radiation Recall Pneumonitis From Immune Checkpoint Inhibitors After Extra Pulmonary Radiation (Walter E. Washington Convention Center, Area D, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_7384;    
    Case 3 is a 68-year-old man with renal clear cell carcinoma and epidural disease, treated with radiation to T6 vertebrae, followed by nivolumab and ipilimumab...Irradiation can induce both acute and long-term pulmonary toxicities. Lung parenchyma, which has not reached inflammatory pneumonitis threshold, can be reactivated with subsequent ICI treatment, creating an additive effect to local inflammation, hitting the threshold for clinically detected pneumonitis.